ArticleJournal of virology2005
How many human immunodeficiency virus type 1-infected target cells can a cytotoxic T-lymphocyte kill?
Article in Journal of virology, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 40 citations in OpenAlex.
- Modelling Role of Protective and Nonprotective HLA Allele Inducing Different HIV Infection Outcomes.Bulletin of mathematical biology · 2024Article
- Cancer-induced immunosuppression can enable effectiveness of immunotherapy through bistability generation: A mathematical and computational examination.Journal of theoretical biology · 2020Article
- Modeling the Treatment of Glioblastoma Multiforme and Cancer Stem Cells with Ordinary Differential Equations.Computational and mathematical methods in medicine · 2016Article
- Estimating the In Vivo Killing Efficacy of Cytotoxic T Lymphocytes across Different Peptide-MHC Complex Densities.PLoS computational biology · 2015Article
- A mathematical model to elucidate brain tumor abrogation by immunotherapy with T11 target structure.PloS one · 2015Article
- Modeling T cell responses to antigenic challenge.Journal of pharmacokinetics and pharmacodynamics · 2014Review
- The route of HIV escape from immune response targeting multiple sites is determined by the cost-benefit tradeoff of escape mutations.PLoS computational biology · 2014Article
- Rates of CTL killing in persistent viral infection in vivo.PLoS computational biology · 2014Article
- The Effect of Interference on the CD8(+) T Cell Escape Rates in HIV.Frontiers in immunology · 2014Article
- Biologically-directed modeling reflects cytolytic clearance of SIV-infected cells in vivo in macaques.PloS one · 2012Article
- The efficiency of the human CD8+ T cell response: how should we quantify it, what determines it, and does it matter?PLoS computational biology · 2012Article
- Article
- Virus replication strategies and the critical CTL numbers required for the control of infection.PLoS computational biology · 2011Article
- Predicting the impact of blocking human immunodeficiency virus type 1 Nef in vivo.Journal of virology · 2009Article
- Estimating in vivo death rates of targets due to CD8 T-cell-mediated killing.Journal of virology · 2008Article
- Improving alloreactive CTL immunotherapy for malignant gliomas using a simulation model of their interactive dynamics.Cancer immunology, immunotherapy : CII · 2008Article
- Revisiting estimates of CTL killing rates in vivo.PloS one · 2007Article
- Estimating the effectiveness of simian immunodeficiency virus-specific CD8+ T cells from the dynamics of viral immune escape.Journal of virology · 2007Article
- Effects of MIP-1α, MIP-3α, and MIP-3β on the Induction of HIV Gag-specific Immune Response with DNA Vaccines.Molecular therapy : the journal of the American Society of Gene Therapy · 2007Article
- Understanding the failure of CD8+ T-cell vaccination against simian/human immunodeficiency virus.Journal of virology · 2007Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
Abstract
The antiviral role of CD8+ cytotoxic T lymphocytes (CTLs) in human immunodeficiency virus type 1 (HIV-1) infection is poorly understood. Specifically, the degree to which CTLs reduce viral replication by killing HIV-1-infected cells in vivo is not known. Here we employ mathematical models of the infection process and CTL action to estimate the rate that CTLs can kill HIV-1-infected cells from in vitro and in vivo data. Our estimates, which are surprisingly consistent considering the disparities between the two experimental systems, demonstrate that on average CTLs can kill from 0.7 to 3 infected target cells per day, with the variability in this figure due to epitope specificity or other factors. These results are compatible with the observed decline in viremia after primary infection being primarily a consequence of CTL activity and have interesting implications for vaccine design.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.